Dr Ann Marie Navar, University of Texas Southwestern Medical Center, Dallas, USA, presents data from a Phase 1 ascending dose study of lepodisiran, in adults with elevated Lp(a) (≥ 75 nmol/L), but no atherosclerotic cardiovascular disease. She also discusses the design of the Phase 2, placebo-controlled ALPACA trial in adults with more elevated Lp(a) (≥ 175 nmol/L), and the Phase 3 ACCLAIM-Lp(a) trial in adults with ASCVD and Lp(a) ≥ 175 nmol/L.
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
